Related Experiment Video
Updated: Jan 16, 2026
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
The effectiveness of the ketogenic diet in treating refractory epilepsy: A study of different seizure forms
Meng Wang1,2, Hongwei Zhang1,2, Pingping Tian1,2
1Neurology Department, Children's Hospital Affiliated to Shandong University, Jinan, China.
Insights
The ketogenic diet (KD) effectively reduces seizures in children with refractory epilepsy. While initial results favor patients with nongeneralized seizures, long-term efficacy shows no significant difference between seizure types.
Area of Science:
- Epilepsy research
- Ketogenic diet therapy
- Pediatric neurology
Background:
- Refractory epilepsy affects children, necessitating alternative treatment strategies.
- The ketogenic diet (KD) is a recognized therapy for drug-resistant epilepsy.
- Understanding KD efficacy across different seizure types is crucial for personalized treatment.
Purpose of the Study:
- To compare the efficacy of the ketogenic diet (KD) in pediatric refractory epilepsy patients with diverse seizure forms.
- To evaluate the correlation between specific seizure types and KD treatment outcomes.
- To assess KD's impact on seizure frequency and reduction rates at 3 and 6 months.
Main Methods:
- Prospective observational cohort study involving 72 children with refractory epilepsy on KD.
- Patients divided into two groups: nongeneralized seizure and full seizure types.
- Monthly seizure frequencies and seizure reduction rates were monitored and compared at 3 and 6 months.
Main Results:
- Both groups showed statistically significant decreases in seizure frequency from baseline after 3 and 6 months of KD.
- At 3 months, the nongeneralized seizure group exhibited significantly lower seizure frequency and greater seizure reduction compared to the full seizure group.
- At 6 months, no statistically significant differences in seizure frequency or reduction were observed between the two groups.
Conclusions:
- The ketogenic diet demonstrates efficacy in reducing seizures in children with refractory epilepsy, irrespective of seizure type.
- Initial benefits of KD may be more pronounced in patients with nongeneralized seizures.
- Long-term (6-month) KD treatment shows comparable effectiveness across different seizure forms in this cohort.
Abstract:
The objective of this study was to compare the efficacy of the ketogenic diet (KD) in patients with refractory epilepsy with different seizure forms and to further evaluate the correlation between seizure types and the efficacy of KD. In this prospective observational cohort study, consecutive children with refractory epilepsy (N = 72) treated with KD were recruited for follow-up. The children were divided into 2 groups: a nongeneralized seizure group and a full seizure group. Monthly seizure frequencies and seizure reduction rate after KDT 3 months and 6 months were compared between 2 groups. Follow-up results at 3 and 6 months showed a decrease in seizure frequency in both the nonprolific and full seizure groups, and the differences in seizure frequency from baseline were statistically significant in both the nonprolific and full seizure groups. After 3 months of KD treatment, the seizure frequency in the nongeneralized seizure group was notably lower than that in the full seizure group. However, after 6 months of KD treatment, there was no statistically significant difference between the seizure frequency of patients in the nongeneralized seizure group and those in the full seizure group. Further findings indicated a greater proportion of seizure reduction in the nongeneralized seizure group than in the full seizure group after 3 months of KD treatment. Statistically significant differences exist between the 2 groups (P＜.05). At the 6 months mark of KD treatment, no statistically significant disparities were observed in the seizure. Finally, this paper further proves the above point by comparing the number of patients who responded to KD through per-protocol population (PP) analysis and intention-to-treat analysis.
More Related Videos
07:35Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
Published on: July 8, 2025
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
Related Concept Videos
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:08Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:14Antiepileptic Drugs: Glutamate Antagonists
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...